124I-Trametinib

N/A

Report date: 2025/12/02 10:28:06

Base Information

Drug Name124I-Trametinib

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Iodine > 124I +[4]

Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 2 inhibitorsDual specificity mitogen-activated protein kinase kinase 1 inhibitors

TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1

Therapy Area/IndicationsThyroid Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWeill Cornell Medicine

China Registration ClassN/A

Develop Information

Active CompaniesWeill Cornell Medicine

Inactive CompaniesN/A

Active IndicationsThyroid Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A